Page 178 - 2020_11-Haematologica-web

2666
Letters to the Editor
2017;130(2):221-228.
3. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of
nivolumab after allogeneic transplantation for relapsed Hodgkin
lymphoma. Blood. 2017;129(18):2471-2478.
4. Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T.
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerg- ing reports of 12 cases. Cancer Chemother Pharmacol. 2018;81(6):1105-1109.
5. Nomura M, Otsuka A, Kondo T, et al. Efficacy and safety of
retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother Pharmacol. 2017;80(5):999-1004.
6. Ansell SM, Armand P, Timmerman JM, et al. Nivolumab re-treat- ment in patients with relapsed/refractory Hodgkin lymphoma. Presented at the 11th International Symposium on Hodgkin Lymphoma. Abstract #0116, 2018 Cologne, Germany.
7. Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 2019;134(14):114-1153.
haematologica | 2020; 105(11)